piqray
novartis biociencias s.a - alpelisibe - agentes antineoplÁsicos
verzenios
eli lilly do brasil ltda - abemaciclibe - inibidores da proteÍna quinase
ibrance
laboratÓrios pfizer ltda - palbociclibe - antineoplasico
aromasin
pfizer brasil ltda - exemestano - antineoplasico
emah
sun farmacÊutica do brasil ltda - exemestano - antineoplasico
exemestano
accord farmacÊutica ltda - exemestano - antineoplasico
exemestano
sun farmacÊutica do brasil ltda - exemestano - antineoplasico
aromasin
laboratÓrios pfizer ltda - antineoplasico
proexty
eurofarma laboratÓrios s.a. - exemestano - agentes antineoplÁsicos
orserdu
stemline therapeutics b.v. - elacestrant - neoplasias do peito - terapia endócrina - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.